Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Actos Archives
Print | Email | Share | Comments (0)

Women Have Double the Fracture Risk with Avandia and Actos

Dec 22, 2008

No effect on bone density among men was seen in any of the studies the researchers analyzed.

Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.

"Women who are taking these drugs should reconsider the options," said lead researcher Dr. Yoon Loke, a clinical senior lecturer at the University of East Anglia in Norwich, in a recent press release.

About 4 million people in the United States take these drugs, which are in a class called thiazolidinediones. Recent studies have also suggested that Avandia increases the risk for heart failure, death, and heart attack, findings that have resulted in new FDA-ordered warning labels about the drug. 

Loke's team evaluated 10 trials that included 13,715 diabetics taking Avandia, Actos, or neither. They found that the two drugs reduced bone density in the spine and hips.  According to their estimates, this loss of bone density doubles the risk of fractures in women taking either drug. 

No effect on bone density among men was seen in any of the studies the researchers analyzed.

Loke speculated in the press release that women are affected because of an interaction between the drugs and estrogen, which weakens bones in women. 

GlaxoSmithKline, the maker of Avandia, said in a press release that this study merely reiterates information that is already known and printed on Avandia's label. 

Source: HealthDay


Categories: Actos, Blood Sugar, Diabetes, Diabetes, Heart Care & Heart Disease, Medications, Medications Research, Pharmacy, Sexual Issues, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Dec 22, 2008

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.